Methimazole interferes with the progression of experimental autoimmune myocarditis in rats

B C Song1, S Matsui, Z P Zong

  • 1Division of Clinical Science, Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan.

Autoimmunity
|March 22, 2002
PubMed

Insights

Methimazole, a hyperthyroidism drug, was found to reduce autoimmune myocarditis (EAM) progression in rats. This study suggests methimazole

Area of Science:

  • Immunology
  • Cardiology
  • Pharmacology

Background:

  • Autoimmune myocarditis (EAM) is a significant cause of myocardial injury.
  • Methimazole is a common treatment for hyperthyroidism.
  • The effect of methimazole on autoimmune-mediated cardiac damage is not well understood.

Purpose of the Study:

  • To investigate the impact of methimazole on experimental autoimmune myocarditis (EAM) in a rat model.
  • To determine if methimazole influences the progression of autoimmune-mediated myocardial injury.

Main Methods:

  • Experimental autoimmune myocarditis (EAM) induced in rats using porcine cardiac myosin.
  • Administration of methimazole to normal and EAM rats.
  • Macroscopic and histopathological examination of cardiac tissue.
  • Flow cytometry analysis of lymphocyte subsets in peripheral blood.

Main Results:

  • Methimazole administration slowed body weight gain in rats but did not cause cardiac changes in normal rats.
  • In EAM rats, methimazole treatment significantly reduced cardiac surface discoloration, myocardial necrosis, inflammation, and fibrosis.
  • Methimazole altered lymphocyte subsets, decreasing the helper/suppressor T cell ratio and B cell proportion, suggesting immunosuppression.

Conclusions:

  • Methimazole interferes with the progression of experimental autoimmune myocarditis in rats.
  • Immunosuppression is a likely mechanism contributing to methimazole's inhibitory effect on EAM.